同源重组缺陷基因面板分析导致同步子宫内膜癌和卵巢癌。

Revista da Associacao Medica Brasileira (1992) Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI:10.1590/1806-9282.20240534
Ferah Kazanci, Zerrin Yılmaz Çelik, Mert Polat, Ferhat Karademir, Ozlem Erdem, Feride İffet Şahin, Mehmet Anil Onan
{"title":"同源重组缺陷基因面板分析导致同步子宫内膜癌和卵巢癌。","authors":"Ferah Kazanci, Zerrin Yılmaz Çelik, Mert Polat, Ferhat Karademir, Ozlem Erdem, Feride İffet Şahin, Mehmet Anil Onan","doi":"10.1590/1806-9282.20240534","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to analyze the genetic alterations of tumors within the scope of the homologous recombination deficiency gene panel in patients diagnosed with synchronous endometrial ovarian cancer who have been followed for over 5 years using next-generation sequencing.</p><p><strong>Methods: </strong>DNA was isolated from the patient's formalin-fixed, paraffin-embedded tissue blocks. Next-generation sequencing was performed using the Illumina capture-based sequencing method. Samples were sequenced using the Sophia HR Solution DNA Kit.</p><p><strong>Results: </strong>Seven patients were included in this study. The ratios of likely pathogenic (LP)/pathogenic (P) somatic mutations in ATM (serine/threonine kinase or Ataxia-telangiectasia mutated gene), BRCA2 (breast cancer type 2 susceptibility gene), BARD1 (BRCA1 associated RING domain 1), TP53 (tumor protein p53), BIRP1 (BRCA1-interacting helicase 1 gene), PALB2 (partner and localizer of BRCA2), and CHECK2 were 21 (48.8%), 8 (18.6%), 5 (11.6%), 3 (6.9%), 2 (4.6%), 2 (4.6%), and 2 (4.6%), respectively, in endometrium, and the ratios of somatic mutations in ATM, BRCA2, TP53, BARD1, RAD54L (DNA repair/recombination protein like), BIRP1, and RAD51D (RAD51 recombinase paralog D) were 24 (60%), 6 (15%), 5 (12.5%), 2 (5%), 2 (5%), 1 (2.5%), and 1 (2.5%), respectively, in ovary. In endometrioid-synchronous endometrial ovarian cancer cases, P/LP mutations were observed in ATM and CHECK2 genes in endometrium and ATM, BRCA2, and TP53 genes in ovary. In two non-endometrioid-synchronous endometrial ovarian cancer cases, CHEK2 (checkpoint kinase 2) mutations were observed in endometrium and ATM and TP53 mutations in ovary, whereas in one case, P/LP mutations in ATM and TP53 genes were common in both tissues.</p><p><strong>Conclusion: </strong>Pathogenic variations confirming the diagnosis of synchronous endometrial ovarian cancer with genetic alterations were identified in all but one case. ATM gene mutation emerged as the most common alteration and has a potential association with a favorable prognosis.</p>","PeriodicalId":94194,"journal":{"name":"Revista da Associacao Medica Brasileira (1992)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444207/pdf/","citationCount":"0","resultStr":"{\"title\":\"Homologous recombination deficiency gene panel analysis results in synchronous endometrial and ovarian cancers.\",\"authors\":\"Ferah Kazanci, Zerrin Yılmaz Çelik, Mert Polat, Ferhat Karademir, Ozlem Erdem, Feride İffet Şahin, Mehmet Anil Onan\",\"doi\":\"10.1590/1806-9282.20240534\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The objective of this study was to analyze the genetic alterations of tumors within the scope of the homologous recombination deficiency gene panel in patients diagnosed with synchronous endometrial ovarian cancer who have been followed for over 5 years using next-generation sequencing.</p><p><strong>Methods: </strong>DNA was isolated from the patient's formalin-fixed, paraffin-embedded tissue blocks. Next-generation sequencing was performed using the Illumina capture-based sequencing method. Samples were sequenced using the Sophia HR Solution DNA Kit.</p><p><strong>Results: </strong>Seven patients were included in this study. The ratios of likely pathogenic (LP)/pathogenic (P) somatic mutations in ATM (serine/threonine kinase or Ataxia-telangiectasia mutated gene), BRCA2 (breast cancer type 2 susceptibility gene), BARD1 (BRCA1 associated RING domain 1), TP53 (tumor protein p53), BIRP1 (BRCA1-interacting helicase 1 gene), PALB2 (partner and localizer of BRCA2), and CHECK2 were 21 (48.8%), 8 (18.6%), 5 (11.6%), 3 (6.9%), 2 (4.6%), 2 (4.6%), and 2 (4.6%), respectively, in endometrium, and the ratios of somatic mutations in ATM, BRCA2, TP53, BARD1, RAD54L (DNA repair/recombination protein like), BIRP1, and RAD51D (RAD51 recombinase paralog D) were 24 (60%), 6 (15%), 5 (12.5%), 2 (5%), 2 (5%), 1 (2.5%), and 1 (2.5%), respectively, in ovary. In endometrioid-synchronous endometrial ovarian cancer cases, P/LP mutations were observed in ATM and CHECK2 genes in endometrium and ATM, BRCA2, and TP53 genes in ovary. In two non-endometrioid-synchronous endometrial ovarian cancer cases, CHEK2 (checkpoint kinase 2) mutations were observed in endometrium and ATM and TP53 mutations in ovary, whereas in one case, P/LP mutations in ATM and TP53 genes were common in both tissues.</p><p><strong>Conclusion: </strong>Pathogenic variations confirming the diagnosis of synchronous endometrial ovarian cancer with genetic alterations were identified in all but one case. ATM gene mutation emerged as the most common alteration and has a potential association with a favorable prognosis.</p>\",\"PeriodicalId\":94194,\"journal\":{\"name\":\"Revista da Associacao Medica Brasileira (1992)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444207/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista da Associacao Medica Brasileira (1992)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1590/1806-9282.20240534\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista da Associacao Medica Brasileira (1992)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/1806-9282.20240534","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

研究目的本研究的目的是利用新一代测序技术,分析被诊断为同步性子宫内膜卵巢癌且随访时间超过5年的患者的同源重组缺失基因面板范围内的肿瘤基因改变情况:从患者福尔马林固定、石蜡包埋的组织块中分离DNA。采用Illumina基于捕获的测序方法进行下一代测序。使用索菲亚 HR 溶液 DNA 试剂盒对样本进行测序:本研究共纳入七名患者。ATM(丝氨酸/苏氨酸激酶或共济失调-特朗根氏症突变基因)、BRCA2(乳腺癌 2 型易感基因)、BARD1(BRCA1 相关基因)中可能致病的体细胞突变(LP)/致病的体细胞突变(P)的比率分别为 0.5%、0.5%、0.5%、0.5%、BARD1(BRCA1 相关 RING 结构域 1)、TP53(肿瘤蛋白 p53)、BIRP1(BRCA1-interacting helicase 1 基因)、PALB2(BRCA2 的伴侣和定位器)和 CHECK2 分别为 21 个(48.子宫内膜中ATM、BRCA2、TP53、BARD1、RAD54L(DNA修复/重组蛋白)、BIRP1和RAD51D(RAD51重组酶旁系D)的体细胞突变比例分别为24(60%)、6(15%)、5(12.5%)、2(5%)、2(5%)、1(2.5%)和 1(2.5%)。在子宫内膜样同步性子宫内膜卵巢癌病例中,子宫内膜的 ATM 和 CHECK2 基因以及卵巢的 ATM、BRCA2 和 TP53 基因均出现了 P/LP 突变。在两例非子宫内膜同步性子宫内膜卵巢癌病例中,子宫内膜中观察到 CHEK2(检查点激酶 2)基因突变,卵巢中观察到 ATM 和 TP53 基因突变,而在一例病例中,ATM 和 TP53 基因的 P/LP 突变在两个组织中都很常见:结论:除一例外,其他所有病例的病因变异均可确诊为伴有基因改变的同步子宫内膜卵巢癌。ATM基因突变是最常见的基因改变,并可能与良好的预后有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Homologous recombination deficiency gene panel analysis results in synchronous endometrial and ovarian cancers.

Objective: The objective of this study was to analyze the genetic alterations of tumors within the scope of the homologous recombination deficiency gene panel in patients diagnosed with synchronous endometrial ovarian cancer who have been followed for over 5 years using next-generation sequencing.

Methods: DNA was isolated from the patient's formalin-fixed, paraffin-embedded tissue blocks. Next-generation sequencing was performed using the Illumina capture-based sequencing method. Samples were sequenced using the Sophia HR Solution DNA Kit.

Results: Seven patients were included in this study. The ratios of likely pathogenic (LP)/pathogenic (P) somatic mutations in ATM (serine/threonine kinase or Ataxia-telangiectasia mutated gene), BRCA2 (breast cancer type 2 susceptibility gene), BARD1 (BRCA1 associated RING domain 1), TP53 (tumor protein p53), BIRP1 (BRCA1-interacting helicase 1 gene), PALB2 (partner and localizer of BRCA2), and CHECK2 were 21 (48.8%), 8 (18.6%), 5 (11.6%), 3 (6.9%), 2 (4.6%), 2 (4.6%), and 2 (4.6%), respectively, in endometrium, and the ratios of somatic mutations in ATM, BRCA2, TP53, BARD1, RAD54L (DNA repair/recombination protein like), BIRP1, and RAD51D (RAD51 recombinase paralog D) were 24 (60%), 6 (15%), 5 (12.5%), 2 (5%), 2 (5%), 1 (2.5%), and 1 (2.5%), respectively, in ovary. In endometrioid-synchronous endometrial ovarian cancer cases, P/LP mutations were observed in ATM and CHECK2 genes in endometrium and ATM, BRCA2, and TP53 genes in ovary. In two non-endometrioid-synchronous endometrial ovarian cancer cases, CHEK2 (checkpoint kinase 2) mutations were observed in endometrium and ATM and TP53 mutations in ovary, whereas in one case, P/LP mutations in ATM and TP53 genes were common in both tissues.

Conclusion: Pathogenic variations confirming the diagnosis of synchronous endometrial ovarian cancer with genetic alterations were identified in all but one case. ATM gene mutation emerged as the most common alteration and has a potential association with a favorable prognosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信